TopoTarget/Spectrum still hopeful with belinostat despite ovarian setback
This article was originally published in Scrip
Executive Summary
Following the recent termination of a Phase II trial of belinostat in ovarian cancer, the next batch of clinical data with the compound in other oncology indications are set to give Denmarks' TopoTarget a clearer idea of the prospects for the anticancer.